Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Corbus Pharmaceuticals Holdings, Inc.CRBP · healthcare
GradeNonecomputable_factors_below_threshold: 6 of 14 inputs computable; 7 are required
Reliability0.87 AUCfailure model, filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate1.03% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size band$120M to $591M assetstotal assets $168.2M[1]
Standard universeoutsiderevenue above $1M and assets above $10M[1-2]
Warningsdilution, short runway, thin data, degenerate inputs
Inputs computable6 of 14
Graded fromfilings received through Mar 9, 2026214 days before the rescan; every figure keyed to the SEC receipt date
Last close$5.252026-10-08; market equity $101.6M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$10$20NovDecJanFebMarAprMayJunJulAugSepOct$5.27
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Feb 21, 2015nonen/aQ1
Apr 21, 2016nonen/aQ2
Mar 21, 2025nonen/aQ3

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 9, 2026; the document on sec.gov.

All references in this report to “Corbus,” the “Company,” “we,” “us,” or “our” mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise, or the context otherwise indicates. Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a clinical stage company focused on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways.

Warnings [top]

Dilution. split-adjusted year-over-year share growth is 45.0%[3-4]
Short runway. cash runway is 3.2 months[5]
Thin data. 6 of 14 grade factors are computable; minimum is 7
Degenerate inputs. latest revenue or assets are at or below the $100,000 validity floor[1-2]

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 45.3
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(8.7%)[1,6-8](6.6%)45.38112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 47.1
Twelve-month failure probability0.34%0.07%78.12482026-06-30
Altman Z double-prime(0.98)[1,9-14](0.31)41.27562025-12-31
Net debt to EBITDAnot computable1.82x
EBITDA must exceed $100,000
Interest coveragenot computable(4.51x)
interest expense must exceed $100,000
Current ratio8.07x[9-10]2.96x22.18392025-12-31
Growth and financing, sleeve percentile 43.8
Revenue growth, three-year compoundnot computable10.0%
current value must be positive and the base must exceed $100,000
Free cash flow growth, three-year compoundnot computable10.9%
four consecutive annual FCF observations are required; found 11
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years36.4%[1,8,15-16]2.1%12.87042025-12-31
Net share issuance, one year45.0%[3-4]2.5%74.96342026-03-06

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(13.8%)8.0%36hotter than 36 of 100 peers
Distance from 52-week high(72.8%)(31.4%)11closer to its high than 11 of 100 peers
EBIT to enterprise value(88.4%)(1.5%)8pricier than 92 of 100 peers
Free cash flow yield(63.3%)(1.0%)9pricier than 91 of 100 peers
Book value to price1.000.2886pricier than 14 of 100 peers
Sales to price0.000.310pricier than 100 of 100 peers
Composite equity issuance, five years153.6%20.3%86more equity-funded than 86 of 100 peers
Relative strength against the sector, log excess return(0.36)(0.14)36ahead of 36 of 100 peers

Inputs: market equity $101.9M; EBIT -$85.3M; free cash flow -$64.5M; book equity $102.2M; sales $0; debt $17.9M; cash $23.4M[17].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(50.4%)✗ fail[6,8]
Operating cash flow above zero-$64.5M✗ fail[7]
Return on assets improved91.8 pts✓ pass[6,8,15,18]
Operating cash flow exceeds net income$14.0M✓ pass[6-7]
Long-term leverage felln/a[1,8,15]
Current ratio improved(487.6 pts)✗ fail[9-10,19-20]
No new shares issued45.0%✗ fail[3-4]
Gross margin improvedn/a
Asset turnover improvedn/a[8,15]
Cash, filings, liquidity
Cash and equivalents$23.4M[5]
Operating cash flow, four quarters-$86.7M[5,7,21-24]
Months of runway3.2
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing64
10-Q received Aug 6, 2026
Median daily dollar volume$4.4M
63 sessions
Days since newest grade input214

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$168.2M2025-12-312026-03-0910-Kfiling · viewer · series
2revenueus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax$02022-12-312023-03-0710-Kfiling · viewer · series
3shares outstandingdei:EntityCommonStockSharesOutstanding17,736,4642026-03-062026-03-0910-Kfiling · viewer · series
4shares outstandingdei:EntityCommonStockSharesOutstanding12,232,2282025-03-072025-03-1110-Kfiling · viewer · series
5cashus-gaap:CashAndCashEquivalentsAtCarryingValue$23.4M2026-06-302026-08-0610-Qfiling · viewer · series
6net incomeus-gaap:NetIncomeLoss-$78.5M2025-12-312026-03-0910-Kfiling · viewer · series
7operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$64.5M2025-12-312026-03-0910-Kfiling · viewer · series
8assetsus-gaap:Assets$155.9M2024-12-312026-03-0910-Kfiling · viewer · series
9current assetsus-gaap:AssetsCurrent$167.0M2025-12-312026-03-0910-Kfiling · viewer · series
10current liabilitiesus-gaap:LiabilitiesCurrent$20.7M2025-12-312026-03-0910-Kfiling · viewer · series
11retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$555.4M2025-12-312026-03-0910-Kfiling · viewer · series
12operating incomeus-gaap:OperatingIncomeLoss-$85.3M2025-12-312026-03-0910-Kfiling · viewer · series
13book equityus-gaap:StockholdersEquity$147.5M2025-12-312026-03-0910-Kfiling · viewer · series
14liabilitiesus-gaap:Liabilities$20.7M2025-12-312026-03-0910-Kfiling · viewer · series
15assetsus-gaap:Assets$28.3M2023-12-312025-03-1110-Kfiling · viewer · series
16assetsus-gaap:Assets$66.3M2022-12-312024-03-1210-Kfiling · viewer · series
17shares outstandingdei:EntityCommonStockSharesOutstanding19,341,2932026-08-042026-08-0610-Qfiling · viewer · series
18net incomeus-gaap:NetIncomeLoss-$40.2M2024-12-312026-03-0910-Kfiling · viewer · series
19current assetsus-gaap:AssetsCurrent$153.0M2024-12-312026-03-0910-Kfiling · viewer · series
20current liabilitiesus-gaap:LiabilitiesCurrent$11.8M2024-12-312026-03-0910-Kfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$55.2M2026-06-302026-08-0610-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$25.6M2026-03-312026-05-1210-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$48.6M2025-09-302025-11-1210-Qfiling · viewer · series
24operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$33.0M2025-06-302026-08-0610-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.